



**REF 10291**  
**HiT II Check**



# Instruction Manual

## Table of Contents

---

1	Intended Use .....	1
2	Clinical Application and Principle of the Assay .....	1
3	Kit Contents .....	2
4	Storage and Shelf Life .....	2
5	Precautions of Use.....	3
6	Sample Collection, Handling and Storage.....	4
7	Assay Procedure .....	4
8	Quantitative Interpretation.....	7
9	Technical Data.....	8
10	Performance Data.....	8
11	Literature .....	9



AIDA GmbH  
Dr.-Karl-Aschoff-Straße 9  
55543 Bad Kreuznach  
Germany  
Phone: +49 671 92065090  
Fax: +49 671 92065091  
Website: [www.aida-diagnostics.com](http://www.aida-diagnostics.com)  
Mail: [info@aida-diagnostics.com](mailto:info@aida-diagnostics.com)

	Product Ref.	10291
	Product Desc.	HiT II Check
	Manual Rev. No.	002: 2024-05-14

## 1 Intended Use

**HiT II Check** is a solid phase enzyme immunoassay for the quantitative detection of antibodies that cause heparin induced thrombocytopenia type II.

## 2 Clinical Application and Principle of the Assay

Heparin induced thrombocytopenia (HiT) is a severe side-effect of heparin treatment and occurs in 1-3 % of the treated patients.

Two distinct types of heparin induced thrombocytopenia can occur: HiT type I has no clinical relevance and is characterised by a transient decrease in platelet counts. It recovers after a few days even if the administration of heparin continues. HiT type II is an immune-mediated form. The platelet counts drop more than 50 % from the baseline 5 to 14 days after first beginning of heparin administration. The affected patients develop antibodies that recognize neoepitopes exposed by the complex of platelet factor 4 and heparin. The antibodies found are most commonly of the IgG subclass with or without IgM and IgA class antibodies. IgM and IgA are rarely found without IgG antibodies. However, the pathogenic effect has been proofed for the IgG subclass whereas the effect of IgM and IgA antibodies is still controversially discussed. The Fc portion of the HiT antibody can bind to the platelet Fc receptor and this interaction triggers activation and aggregation of the platelets. Activated platelets release PF4, thus perpetuating the cycle of heparin-induced platelet activation. The platelet activation leads to the production of platelet factor 4 and prothrombotic platelet microparticles. Heparin-like molecules (heparan sulfate) on the surface of endothelial cells are also able to form a complex with platelet factor 4 that can be recognized by HiT antibodies. That, in turn, can induce tissue factor expression with further activation of the coagulation cascade and thrombin generation. It leads to an increased risk for new arterial and venous thromboembolic complications that can be lethal in 10-15 % of the patients.

An early diagnosis and a replacement with a suitable alternative anticoagulant can clearly minimize the complication rate.

### Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient's antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The intensity of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

	Product Ref.	10291
	Product Desc.	HiT II Check
	Manual Rev. No.	002: 2024-05-14

### 3 Kit Contents

TO BE RECONSTITUTED				
Item	Quantity	Cap color	Solution color	Description / Contents
Sample Buffer (5x)	1 x 20ml	White	Yellow	5 x concentrated Tris, sodium chloride (NaCl), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Wash Buffer (50x)	1 x 20ml	White	Green	50 x concentrated Tris, NaCl, Tween 20, sodium azide < 0.1% (preservative)
READY TO USE				
Item	Quantity	Cap color	Solution color	Description / Contents
Negative Control	1 x 1.5ml	Green	Colorless	Control material (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Positive Control	1 x 1.5ml	Red	Yellow	Control material (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Calibrators	6 x 1.5ml	White	Yellow *	Concentration of each calibrator: 0, 3, 10, 30, 100, 300 U/ml. Calibrator material (diluted), bovine serum albumin (BSA), sodium azide < 0.1% (preservative)
Conjugate, IgA/G/M	1 x 15ml	White	Red	Containing: Immunoglobulins conjugated to horseradish peroxidase, bovine serum albumin (BSA)
TMB Substrate	1 x 15ml	Black	Colorless	Stabilized tetramethylbenzidine and hydrogen peroxide (TMB/H <sub>2</sub> O <sub>2</sub> )
Stop Solution	1 x 15ml	White	Colorless	1M Hydrochloric Acid
Microtiter plate	12 x 8 well strips	N/A	N/A	With breakaway microwells. Refer to paragraph 1 for coating.
* Color increasing with concentration				
MATERIALS REQUIRED, BUT NOT PROVIDED				
Microtiter plate reader 450 nm reading filter and recommended 620 nm reference filter (600-690 nm). Glass ware (cylinder 100-1000ml), test tubes for dilutions. Vortex mixer, precision pipettes (10, 100, 200, 500, 1000 µl) or adjustable multipipette (100-1000µl). Microplate washing device (300 µl repeating or multichannel pipette or automated system), adsorbent paper. Our tests are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur.Ph. 4th ed.).				

### 4 Storage and Shelf Life

Store all reagents and the microplate at 2-8°C/35.6-46.4°F, in their original containers. Once prepared, reconstituted solutions are stable at 2-8°C/35.6-46.4°F for 1 month. Reagents and the microplate shall be used within the expiry date indicated on each component, only. Avoid intense exposure of TMB solution to light. Store microplates in designated foil, including the desiccant, and seal tightly.

	Product Ref.	10291
	Product Desc.	HiT II Check
	Manual Rev. No.	002: 2024-05-14

## 5 Precautions of Use

### 5.1 Health hazard data

**THIS PRODUCT IS FOR IN VITRO DIAGNOSTIC USE ONLY.** Thus, only staff trained and specially advised in methods of in vitro diagnostics may perform the kit. Although this product is not considered particularly toxic or dangerous in conditions of the intended use, refer to the following for maximum safety:

#### ***Recommendations and precautions***

This kit contains potentially hazardous components. Though kit reagents are not classified being irritant to eyes and skin we recommend to avoid contact with eyes and skin and wear disposable gloves.

**WARNING !** Calibrators, Controls and Buffers contain sodium azide ( $\text{NaN}_3$ ) as a preservative.  $\text{NaN}_3$  may be toxic if ingested or adsorbed by skin or eyes.  $\text{NaN}_3$  may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. Please refer to decontamination procedures as outlined by CDC or other local/national guidelines.

**Do not smoke, eat or drink when manipulating the kit. Do not pipette by mouth.**

All biological source material used for some reagents of this kit has been tested by approved methods and found negative for HbsAg, Hepatitis C and HIV 1. However, no test can guarantee the absence of viral agents in such material completely. Thus handle these as if capable of transmitting infectious diseases and according to national requirements.

The kit contains material of animal origin as stated in the table of contents, handle according to national requirements.

### 5.2 General directions for use

In case that the product information, including the labeling, is defective or incorrect please contact the manufacturer or the supplier of the test kit.

Do not mix or substitute Controls, Calibrators, Conjugates or microplates from different lot numbers. This may lead to variations in the results.

Allow all components to reach room temperature (20-32°C/68-89.6°F) before use, mix well and follow the recommended incubation scheme for an optimum performance of the test.

**Incubation: We recommend test performance at 30°C/86°F for automated systems.**

Never expose components to higher temperature than 37°C/ 98.6°F.

Always pipette substrate solution with brand new tips only. Protect this reagent from light. Never pipette conjugate with tips used with other reagents prior.

**A definite clinical diagnosis should not be based on the results of the performed test only, but should be made by the physician after all clinical and laboratory findings have been evaluated. The diagnosis is to be verified using different diagnostic methods.**

	Product Ref.	10291
	Product Desc.	HiT II Check
	Manual Rev. No.	002: 2024-05-14

## 6 Sample Collection, Handling and Storage

Use preferentially freshly collected serum samples. Blood withdrawal must follow national requirements. Do not use icteric, lipemic, hemolysed or bacterially contaminated samples. Sera with particles should be cleared by low speed centrifugation (<1000 x g). Blood samples should be collected in clean, dry and empty tubes.

After separation, the serum samples should be used during the first 8h, respectively stored tightly closed at 2-8°C/35.6-46.4°F up to 48h, or frozen at -20°C/-4°F for longer periods. (Thomas: Labor und Diagnose; CLSI Guideline GP44-A4)

## 7 Assay Procedure

### 7.1 Preparations prior to starting

#### **Dilute concentrated reagents:**

Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 ml plus 80 ml).

Dilute the concentrated wash buffer 1:50 with distilled water (e.g. 20 ml plus 980 ml).

To avoid mistakes we suggest to mark the cap of the different calibrators.

#### **Samples:**

Dilute serum samples 1:101 with sample buffer (1x)

e.g. 1000 µl sample buffer (1x) + 10 µl serum. Mix well !

#### **Washing:**

Prepare 20 ml of diluted wash buffer (1x) per 8 wells or 200 ml for 96 wells

e.g. 4 ml concentrate plus 196 ml distilled water.

#### **Automated washing:**

Consider excess volumes required for setting up the instrument and dead volume of robot pipette.

#### **Manual washing:**

Discard liquid from wells by inverting the plate. Knock the microwell frame with wells downside vigorously on clean adsorbent paper. Pipette 300 µl of diluted wash buffer into each well, wait for 20 seconds. Repeat the whole procedure twice again.

#### **Microplates:**

Calculate the number of wells required for the test. Remove unused wells from the frame, replace and store in the provided plastic bag, together with desiccant, seal tightly (2-8°C/35.6-46.4°F).

## 7.2 Pipetting Scheme

We suggest pipetting calibrators, controls and samples as follows:

For *QUANTITATIVE* interpretation

	1	2	3	4...
A	Cal A	Cal E	P1	
B	Cal A	Cal E	P1	
C	Cal B	Cal F	P2	
D	Cal B	Cal F	P2	
E	Cal C	PC	P3	
F	Cal C	PC	P3	
G	Cal D	NC	...	
H	Cal D	NC	...	

CalA: calibrator A

CalB: calibrator B

CalC: calibrator C

CalD: calibrator D

CalE: calibrator E

CalF: calibrator F

PC: positive control




NC: negative control

P1: patient 1


P2: patient 2




P3: patient 3



## 7.3 Test Steps




Step	Description
1.	Ensure preparations from step 7.1 above have been carried out prior to pipetting.
2.	Use the following steps in accordance with quantitative interpretation results desired:
<b>CONTROLS &amp; SAMPLES</b>	
3.	 <p>Pipette into the designated wells as described in chapter 7.2 above, 100 µl of either:  Calibrators (CAL.A to CAL.F) for <i>QUANTITATIVE</i> interp.  and 100 µl of each of the following:</p> <ul style="list-style-type: none"> <li>Negative control (NC) and Positive control (PC), and</li> <li>Patients diluted serum (P1, P2...)</li> </ul>
4.	 <p>Incubate for 30 minutes at 20-32°C/68-89.6°F.</p>
5.	 <p>Wash 3x with 300 µl washing buffer (diluted 1:50).</p>



<div> autoimmune diagnostic assays</div>		Product Ref.	10291
		Product Desc.	HiT II Check
		Manual Rev. No.	002: 2024-05-14

CONJUGATE		
6.	<div><div>CONJ</div></div>	Pipette 100 µl conjugate into each well.
7.	<div></div>	Incubate for 30 minutes at 20-32°C/68-89.6°F.
8.	<div><div>WASHB</div></div>	Wash 3x with 300 µl washing buffer (diluted 1:50).

SUBSTRATE		
9.	<div><div>SUB</div></div>	Pipette 100 µl TMB substrate into each well.
10.	<div></div>	Incubate for 30 minutes at 20-32°C/68-89.6°F, protected from intense light.

STOP		
11.	<div><div>STOP</div></div>	Pipette 100 µl stop solution into each well, using the same order as pipetting the substrate.
12.	<div></div>	Incubate 5 minutes minimum.
13.		Agitate plate carefully for 5 sec.
14.	<div><div>OD<sub>450</sub> - OD<sub>620</sub> 450/620 nm</div></div>	Read absorbance at 450 nm (recommended 450/620 nm) within 30 minutes.

## 8 Quantitative Interpretation

For **quantitative interpretation** establish the standard curve by plotting the optical density (OD) of each calibrator (y-axis) with respect to the corresponding concentration values in U/ml (x-axis). For best results we recommend log/lin coordinates and 4-Parameter Fit. From the OD of each sample, read the corresponding antibody concentrations expressed in U/ml.

Normal Range	Equivocal Range	Positive Results
< 16 U/ml	16 - 24 U/ml	>24 U/ml

### *Example of a standard curve*

**Do NOT use this example for interpreting patient's result**

Calibrators IgA/G/M	OD 450/620 nm	CV % (Variation)
0 U/ml	0,025	0,0
3 U/ml	0,139	3,5
10 U/ml	0,283	4,3
30 U/ml	0,598	4,0
100 U/ml	1,224	3,6
300 U/ml	2,123	2,8

### *Example of calculation*

Patient	Replicate (OD)	Mean (OD)	Result (U/ml)
P 01	0,793/0,801	0,797	47,7
P 02	0,308/0,333	0,321	12,1

**Do not use this example for interpreting patients results!**

Samples above the highest calibrator range should be reported as >Max. They should be diluted as appropriate and re-assayed. Samples below calibrator range should be reported as < Min.

For lot specific data, see enclosed quality control leaflet. Medical laboratories might perform an in-house quality control by using own controls and/or internal pooled sera, as foreseen by national regulations.

Each laboratory should establish its own normal range based upon its own techniques, controls, equipment and patient population according to their own established procedures.

In case that the values of the controls do not meet the criteria the test is invalid and has to be repeated.

The following technical issues should be verified: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, photometer, incubation conditions and washing methods.

If the items tested show aberrant values or any kind of deviation or that the validation criteria are not met without explicable cause please contact the manufacturer or the supplier of the test kit.

	Product Ref.	10291
	Product Desc.	HiT II Check
	Manual Rev. No.	002: 2024-05-14

## 9 Technical Data

Sample material:	serum
Sample volume:	10 µl of sample diluted 1:101 with 1x sample buffer
Total incubation time:	90 minutes at 20-32°C/68-89.6°F
Calibration range:	0-300 U/ml
Analytical sensitivity:	1.0 U/ml
Storage:	at 2-8°C/35.6-46.4°F use original vials only.
Number of determinations:	96 tests

## 10 Performance Data

### 10.1 Analytical sensitivity

Testing sample buffer 30 times on HiT II Check gave an analytical sensitivity of 1.0 U/ml.

### 10.2 Specificity and sensitivity

The sensitivity of the HiT II Check was determined to be 100 % in comparison to plasma samples with known immune status. Clinically defined plasma samples show a specificity of 90%.

### 10.3 Linearity

Chosen plasma samples have been tested with this kit and found to dilute linearly. However, due to the heterogeneous nature of human autoantibodies there might be samples that do not follow this rule.

Sample No.	Dilution Factor	Measured (U/ml)	Expected (U/ml)	Recovery (%)
1	1 / 100	77,6	80,0	97,0
	1 / 200	37,5	40,0	93,8
	1 / 400	18,8	20,0	94,0
	1 / 800	9,1	10,0	91,0
2	1 / 100	7,7	8,0	96,3
	1 / 200	3,8	4,0	95,0
	1 / 400	2,2	2,0	110,0
	1 / 800	1,0	1,0	100,0

	Product Ref.	10291
	Product Desc.	HiT II Check
	Manual Rev. No.	002: 2024-05-14

## 10.4 Precision

To determine the precision of the assay, the variability (intra and inter-assay) was assessed by examining its reproducibility on three plasma samples selected to represent a range over the standard curve.

Intra-assay		
Sample No.	Mean (U/ml)	CV (%)
1	9,8	1,3
2	120,2	9,8
3	210,2	10,0

Inter-assay		
Sample No.	Mean (U/ml)	CV (%)
1	10,2	1,0
2	106,6	9,5
3	208,6	6,3

## 10.5 Calibration

Due to the lack of international reference calibration this assay is calibrated in arbitrary units (U/ml).

## 11 Literature

**Warkentin T.E. (2005).** New approaches to the diagnosis of heparin induced thrombocytopenia. Chest 127: 35-45.

**Franchini M. (2005).** Heparin induced thrombocytopenia: an update. Thrombosis Journal 3: 14.

**Warkentin T.E. (2004).** Heparin induced thrombocytopenia. Diagnosis and treatment Circulation 110: 454-458.

**Lindhoff-Last E., Gerdson F., Ackermann H., Bauersachs R. (2001).** Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin induced thrombocytopenia. British Journal of Haematology 113: 886-890.

**Warkentin T.E., Chong B.H., Greinacher A. (1998).** Heparin induced thrombocytopenia: Towards consensus. Thrombosis and Haemostasis 79: 1-7




















**Ziporen L., Li Z.Q., Park K.S., Sabnekar P., Liu W.Y., Arepally G., Shoenfeld Y., Kieber-Emmons T., Cines D.B., Poncz M. (1998).** Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombo cytopenia. Blood 92, 9: 3250-3259.

**Greinacher A., Poetzsch B., Amiral J., Dummel V., Eichner A., Mueller-Eckhardt C. (1994).** Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thrombosis and Haemostasis 71: 247-251.

**Chong B.H., Fawaz I., Chesterman C.N., Berndt M.C. (1989).** Heparin induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. British Journal of Haematology 73: 235-240.

**Lothar Thomas:** Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik., 8. Auflage, TH Books

**CLSI Guideline GP44-A4:** Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests

	- Diagnosi in vitro - Pour diagnostic in vitro - In Vitro Diagnostikum - Para uso Diagnóstico in vitro	- For in vitro diagnostic use - Para uso diagnóstico in vitro - In Vitro Διαγνωστικό μέσο
	* Numero d'ordine * Référence Catalogue * Bestellnummer * Número de catálogo	* Catalogue number * Numéro de catálogo * Αριθμός παραγγελίας
	* Descrizione lotto * Lot * Chargen Bezeichnung * Lote	* Lot * Lote * Χαρακτηρισμός παρτίδας
	* Identificatore univoco del dispositivo * Identifiant unique de l'appareil * eindeutige Produktidentifizierung * Identificador único do dispositivo	* Unique Device Identifier * Identificador único del dispositivo * Μοναδικό αναγνωριστικό συσκευής
	* Conformità europea * Déclaration CE de Conformité * Europäische Konformität * Declaração CE de Conformidade	* EC Declaration of Conformity * Declaración CE de Conformidad * Ευρωπαϊκή συμφωνία
	* 96 determinazioni * 96 tests * 96 Bestimmungen * 96 Testes	* 96 tests * 96 pruebas * 96 προσδιορισμοί
	* Rispettare le istruzioni per l'uso * Voir les instructions d'utilisation * Gebrauchsanweisung beachten * Ver as instruções de uso	* See instructions for use * Ver las instrucciones de uso * Λάβετε υπόψη τις οδηγίες χρήσης
	* Da utilizzarsi entro * Utiliser avant le * Verwendbar bis * Utilizar antes de	* Use by * Utilizar antes de * Χρήση μέχρι
	* Conservare a 2-8°C * Conserver à 2-8°C * Lagerung bei 2-8°C * Conservar entre 2-8°C	* Store at 2-8°C (35.6-46.4°F) * Conservar a 2-8°C * Φυλάσσεται στους 2-8°C
	* Prodotto da * Fabriqué par * Hergestellt von * Fabricado por	* Manufactured by * Fabricado por * Κατασκευάζεται από
	* Controllo positivo * Contrôle Positif * Positiv Kontrolle * Controllo positivo	* Positive Control * Control Positivo * Θετικός ορός ελέγχου
	* Controllo negativo * Contrôle Négatif * Negativ Kontrolle * Controllo negativo	* Negative Control * Control Negativo * Αρνητικός ορός ελέγχου
	* Calibratore * Etalon * Kalibrator * Calibrador	* Calibrator * Calibrador * Αντιδραστήριο βαθμονόμησης
	* Coniugato * Conjugué * Konjugat * Conjugado	* Conjugate * Conjugado * Σύζευγμα
	* Micropiastra rivestita * Microplaque sensibilisée * Beschichtete Mikrotiterplatte * Microplaca revestida	* Coated microtiter plate * Microplaca sensibilizada * Επικαλυμμένη μικροτίτλακα
	* Tampone di lavaggio * Tampon de Lavage * Waschpuffer * Solução de lavagem	* Wash buffer * Solución de lavado * Ρυθμιστικό διάλυμα πλύσης
	* Tampone substrato * Substrat * Substratpuffer * Substrato	* Substrate buffer * Tampón sustrato * Ρυθμιστικό διάλυμα υποστρώματος
	* Reagente bloccante * Solution d'Arrêt * Stopreagenz * Solução de paragem	* Stop solution * Solución de parada * Αντιδραστήριο διακοπής αντίδρασης
	* Tampone campione * Tampon Echantillons * Probenpuffer * Diluente de amostra	* Sample buffer * Tampón Muestras * Ρυθμιστικό διάλυμα δειγμάτων